BCL2L1 and cancer: Noticeably, these anti-cancer drugs developed for oncogene-addicted cancers were re-discovered as senolytics: the Bcr-Abl kinase inhibitor dasatinib, the Bcl-2/BclxL inhibitors Venetoclax (ABT-199) and Navitoclax (ABT-263) and Hsp-90 inhibitors (geldanamycin).